NanoViricides, Inc. (NASDAQ:NNVC)

BRIEF

published on 02/10/2026 at 14:35, 6 months 4 days ago

NanoViricides Pursues Orphan Drug Designation for Measles Treatment

NanoViricides NV-387 FDA Approval Orphan Drug Designation Measles Treatment
PRESS RELEASE

published on 02/10/2026 at 14:30, 6 months 4 days ago

Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides
NanoViricides files for Orphan Drug Designation for NV-387 as Measles treatment with potential FDA incentives. Strong in vivo activity against Measles shown in humanized animal model study

NanoViricides NV-387 Orphan Drug Designation Measles Treatment FDA Incentives
BRIEF

published on 02/02/2026 at 14:35, 6 months 12 days ago

NanoViricides présente des avancées antivirales avec le NV-387

NanoViricides NV-387 Essais Cliniques À Large Spectre Thérapie Antivirale
BRIEF

published on 02/02/2026 at 14:35, 6 months 12 days ago

NanoViricides Showcases Antiviral Advancements with NV-387

NanoViricides NV-387 Clinical Trials Antiviral Therapy Broad-spectrum
PRESS RELEASE

published on 02/02/2026 at 14:30, 6 months 12 days ago

NanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam Torres
NanoViricides, Inc. announces President Dr. Anil R. Diwan's interview on Mission Matters Podcast discussing revolutionary antiviral drugs development and NV-387 efficacy against various viruses

NV-387 Antiviral Drugs NanoViricides Inc. Dr. Anil R. Diwan Mission Matters Podcast
BRIEF

published on 01/13/2026 at 14:35, 7 months 1 day ago

NanoViricides Highlights Need for Broad-Spectrum Antivirals Amid Influenza Surge

NV-387 Respiratory Infections Broad-spectrum Antivirals Influenza Virus Antiviral Resistance
BRIEF

published on 01/13/2026 at 14:35, 7 months 1 day ago

NanoViricides souligne le besoin d'antiviraux à large spectre face à la recrudescence de la grippe

NV-387 Infections Respiratoires Antiviraux À Large Spectre Virus De La Grippe Résistance Antivirale
PRESS RELEASE

published on 01/13/2026 at 14:30, 7 months 1 day ago

NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave - NV-387 is Effective Against H3N2
NanoViricides, Inc. declares need for broad-spectrum antivirals amid severe influenza epidemic, highlighting potential of NV-387 against multiple viruses

NanoViricides NV-387 Respiratory Viruses Broad-spectrum Antivirals Influenza Epidemic
BRIEF

published on 12/01/2025 at 14:35, 8 months 13 days ago

NanoViricides Inks Agreement for Orphan Drug Strategy with Only Orphans Cote

NanoViricides NV-387 Regulatory Pathway Broad-spectrum Antiviral Orphan Drug Strategy
BRIEF

published on 12/01/2025 at 14:35, 8 months 13 days ago

NanoViricides signe un accord avec Only Orphans Cote concernant sa stratégie en matière de médicaments orphelins.

NanoViricides NV-387 Voie Réglementaire Antiviral À Large Spectre Stratégie Des Médicaments Orphelins

Published on 08/15/2026 at 00:50, 5 hours 11 minutes ago

Revive Therapeutics Reports Grant of Options
Published on 08/15/2026 at 00:15, 5 hours 46 minutes ago

Full Circle Lithium Announces Closing of Private Placement
Published on 08/14/2026 at 23:45, 6 hours 16 minutes ago

AI/ML Innovations Inc. Announces Proposed Private Placement
Published on 08/14/2026 at 23:25, 6 hours 36 minutes ago

NuRAN Wireless Closes $7.6 Million Financing
Published on 08/14/2026 at 23:00, 7 hours 1 minute ago

Medicure Reports Financial Results for Quarter Ended June 30, 2026 and Schedules August 17, 2026 Conference Call

View all ACCESSWIRE

Published on 08/14/2026 at 18:29, 11 hours 32 minutes ago

Designated Persons Notifications
Published on 08/14/2026 at 18:29, 11 hours 32 minutes ago

Designated Persons Notifications
Published on 08/14/2026 at 18:15, 11 hours 46 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 08/14/2026 at 16:05, 13 hours 56 minutes ago

GATORADE WELCOMES AITANA BONMATÍ TO TEAM GATORADE AHEAD OF THE NEW FOOTBALL SEASON
Published on 08/14/2026 at 15:29, 14 hours 32 minutes ago

Tradegate AG publishes its half-year report

View all EQS

Published on 08/13/2026 at 18:00, 1 day 12 hours ago

Chiffre d’affaires du 1er trimestre 2026-27 : 14,4 M€
Published on 08/11/2026 at 17:45, 3 days 12 hours ago

DAMARTEX / Droits de vote bruts et réels au 31 juillet 2026
Published on 08/11/2026 at 17:40, 3 days 12 hours ago

Infotel : Déclaration des transactions sur actions propres réalisées du 3 au 7 août 2026 dans le cadre du programme de rachat d’actions
Published on 08/10/2026 at 18:00, 4 days 12 hours ago

AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 4 days 12 hours ago

AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026

View all LES ECHOS COMFI WIRE

News